1,092 results on '"Koomen, John"'
Search Results
202. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling
203. Integrated proteomics-based physical and functional mapping of AXL kinase signaling pathways and inhibitors define its role in cell migration
204. Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women
205. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
206. Abstract P018: Integrative proteomics of PARP1 protein complexes and post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors
207. Acid Hydrolysis of Proteins in Matrix Assisted Laser Desorption Ionization Matrices
208. IKKϵ phosphorylation of estrogen receptor α Ser-167 and contribution to tamoxifen resistance in breast cancer.
209. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
210. An ET-CURE Pilot Project Supporting Undergraduate Training in Cancer Research, Emerging Technology, and Health Disparities
211. Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies
212. Proteomic Contributions to Personalized Cancer Care
213. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output
214. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer
215. Abstract 734: Macrophage tumor cell metabolic interactions induce therapeutic resistance in prostate cancer
216. Abstract 1116: HDAC8 activity regulates stress induced phenotype switching in melanoma
217. Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling
218. Abstract 1635: Sirt2 blockade promotes T cell metabolism and restores the anti-tumor immunity
219. Fucosylated Proteome Profiling Identifies a Fucosylated, Non-Ribosomal, Stress-Responsive Species of Ribosomal Protein S3
220. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma
221. A Mutational Survey of Acral Nevi
222. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determine myeloma CAR-T outcomes
223. Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel
224. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.
225. HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
226. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
227. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
228. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma
229. Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
230. Anion template effect on the self-assembly and interconversion of metallacyclophanes
231. Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry
232. Lipid/peptide/nucleotide separation with MALDI-ion mobility-TOF MS
233. Oligonucleotide analysis with MALDI–ion-mobility–TOFMS
234. A study of peptide—Peptide interactions using MALDI ion mobility o-TOF and ESI mass spectrometry
235. Involvement of the Conserved Adaptor Protein Alix in Actin Cytoskeleton Assembly
236. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response
237. 280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients
238. 93 Targeting sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment
239. 235 Antigen presentation pathways prime melanoma patients for more durable response to anti–PD-1 checkpoint blockade therapy
240. Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment
241. LC-HRMS of derivatized urinary estrogens and estrogen metabolites in postmenopausal women
242. Abstract PR13: PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas
243. Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach
244. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells
245. Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial
246. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
247. TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes
248. CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.
249. Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
250. Translational pathology, genomics and the development of systemic therapies for acral melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.